Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients With CLL or SLL

NCT06849713 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma (SLL)

Interventions

DRUG: Zanubrutinib
DRUG: Sonrotoclax
DRUG: Obinutuzumab

Sponsor

Massachusetts General Hospital

Collaborators

[object Object]